, Le jeûne induirait une diminution de l'inflammation articulaire, cependant il n'est pas recommandé du fait des risques qu'il comporte. Le régime méditerranéen (légumes, fruits, céréales, huile d'olive et poisson) semble améliorer la qualité de vie des patients avec un bénéfice cardiovasculaire démontré, cependant il n'a pas montré d'amélioration des paramètres biologiques, Les régimes végétariens et d'exclusion ne sont pas recommandés en raison du risque de carences qu'ils entraînent

, Il est donc important de prendre conseil auprès d'un spécialiste en cas de changement d'alimentation, afin d'éviter les carences alimentaires et les erreurs de régime

, En cas de surcharge pondérale, il est recommandé d'avoir une alimentation moins riche en calories

, La prise de corticoïdes entraîne également une modification du régime alimentaire : faible en sucre et en sel, apports en calcium alimentaire

, du fait des interactions qu'il peut engendrer avec les différents traitements. Le tabac est déconseillé

, Le pharmacien est aussi force de conseils hygiénodiététiques, p.179

B. Genetet and D. Sicard, Histoire de l'immunologie, Presses universitaires de France

A. Moulin and N. K. Jerne, Texte imprimé] : histoire de l'immunologie de Pasteur au SIDA. Paris : Presses universitaires de France, impr, Impr. des PUF, p.41, 1991.

S. Y. Tan, S. P. Grimes, and . Ehrlich, 1854-1915): man with the magic bullet, Singapore Med J, vol.51, issue.11, pp.842-845, 2010.

R. S. Schwartz and . Paul, Ehrlich's Magic Bullets, N Engl J Med. 11 mars, vol.350, issue.11, pp.1079-80, 2004.

G. F. Gensini, A. A. Conti, and D. Lippi, The contributions of Paul Ehrlich to infectious disease, J Infect. mars, vol.54, issue.3, pp.221-225, 2007.

C. Milstein, From the structure of antibodies to the diversification of the immune response, Biosci Rep. oct, vol.24, issue.4-5, pp.280-301, 2004.

T. A. Springer, Cesar Milstein, the father of modern immunology, Nat Immunol, issue.6, p.501, 2002.
DOI : 10.1038/ni0602-501

D. Ribatti, From the discovery of monoclonal antibodies to their therapeutic application: An historical reappraisal, Immunol Lett. sept, vol.161, issue.1, pp.96-105, 2014.

S. Siberil, C. Dutertre, C. Boix, and J. Teillaud, Anticorps monoclonaux à usage thérapeutique : un peu d'histoire, beaucoup d'ingénierie, et ? quelques succès cliniques, Transfus Clin Biol. juin, vol.12, issue.2, pp.114-136, 2005.
DOI : 10.1016/j.tracli.2005.04.016

M. Neuberger and . César-milstein, Curr Biol CB. 30 avr, vol.12, issue.9, pp.308-318, 1927.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé

J. Kuby, J. A. Owen, J. Punt, S. A. Stranford, P. P. Jones et al.,

D. K. Male, J. Brostoff, I. M. Roitt, P. L. Masson, and . Immunologie,

. Issy-lesmoulineaux, , 2007.

, Association des Collèges des Enseignants d'Immunologie. Immunologie fondamentale et immunopathologie

I. M. Roitt, P. J. Delves, S. J. Martin, D. R. Burton, and P. L. Masson, Fondements de l'immunologie, 2008.

G. Mayer and D. Hudrisier, Génétique des immunoglobulines

M. Moutschen and A. Scheen, Bases immunologiques à la compréhension du concept d'anticorps monoclonal, Rev Médicale Liège. Mai, vol.64, issue.5-6, pp.237-280, 2009.

A. J. Scheen, Nomenclature internationale des différents types d'anticorps monoclonaux, Rev Médicale Liège, vol.64, issue.5-6, pp.244-251, 2009.

C. Bardet and J. Cook-moreau, Les anticorps monoclonaux : apprenons à les connaître, Actual Pharm. nov, vol.52, issue.530, pp.18-22, 2013.
DOI : 10.1016/j.actpha.2013.09.005

V. I. Mistretta, E. Cavalier, J. Collette, and J. P. Chapelle,

, Rev Médicale Liège. 5 juin, vol.64, issue.5-6, pp.248-52, 2009.

J. Teillaud and . Qu, est-ce qu'une biothérapie ? L'exemple des anticorps monoclonaux, Presse Médicale. mai, vol.38, issue.5, pp.825-856, 2009.
DOI : 10.1016/j.lpm.2008.12.025

D. Bourel and J. Teillaud, Anticorps monoclonaux : tours et détours technologiques pour de nouveaux espoirs thérapeutiques, C R Biol. avr, vol.329, issue.4, pp.217-244, 2006.

M. A. Roguska, J. T. Pedersen, C. A. Keddy, A. H. Henry, S. J. Searle et al., Humanization of murine monoclonal antibodies through variable domain resurfacing, Proc Natl Acad Sci U S A. 1 févr, vol.91, issue.3, pp.969-73, 1994.

A. Lanzavecchia, D. Corti, and F. Sallusto, Human monoclonal antibodies by immortalization of memory B cells, Curr Opin Biotechnol. déc, vol.18, issue.6, pp.523-531, 2007.

C. A. Borrebaeck, Strategy for the production of human monoclonal antibodies using in vitro activated B cells, J Immunol Methods, vol.123, issue.2, pp.157-65, 1989.

N. Lonberg, L. D. Taylor, F. A. Harding, M. Trounstine, K. M. Higgins et al., Antigen-specific human antibodies from mice comprising four distinct genetic modifications, Nature. 28 avr, vol.368, issue.6474, pp.856-865, 1994.

L. L. Green, M. C. Hardy, C. E. Maynard-currie, H. Tsuda, D. M. Louie et al., Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs, Nat Genet. mai, vol.7, issue.1, pp.13-21, 1994.

K. Tomizuka, T. Shinohara, H. Yoshida, H. Uejima, A. Ohguma et al., Double trans-chromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and ? loci and expression of fully human antibodies, Proc Natl Acad Sci, vol.18, issue.2, p.722, 2000.

A. Frenzel, T. Schirrmann, and M. Hust, Phage display-derived human antibodies in clinical development and therapy. mAbs, vol.8, pp.1177-94, 2016.

J. Hanes, C. Schaffitzel, A. Knappik, and A. Plückthun, Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display, Nat Biotechnol. déc, vol.18, issue.12, pp.1287-92, 2000.

S. E. Chin, F. Ferraro, M. Groves, M. Liang, T. J. Vaughan et al., Isolation of highaffinity, neutralizing anti-idiotype antibodies by phage and ribosome display for application in immunogenicity and pharmacokinetic analyses, J Immunol Methods. janv, vol.416, pp.49-58, 2015.

J. M. Reichert, Antibodies to watch in 2017, mAbs. 17 févr, vol.9, issue.2, pp.167-81, 2017.

, Top 10 Best-selling Biologicals of 2015, 2016.

, Monoclonal Antibody Therapeutics Market to be Worth US$245.8 Billion by 2024: Spike in Cancer Cases Around the World to Ensure Swift Uptake, Predicts TMR

. Aboutpharma, , 2017.

, Monoclonal Antibodies (mAbs) Market Size Worth $138.6 Billion By, p.2024

. Marchés-|-innate and . Pharma,

. Disponible,

, Bientôt des anticorps monoclonaux (AcMo) pour toutes les maladies ? | LEEM-Les entreprises du médicament

, Monoclonal Antibodies (mAbs) Market Size | Industry Report, pp.2013-2024

C. Marcelli and . Rhumatologie, Les référentiels des collèges, 2015.

J. Sany, La polyarthrite rhumatoïde de l'adulte, 2003.

C. Menkès, La polyarthrite rhumatoïde de l'adulte, Le Quotidien du médecin, 2004.

, Polyarthrite rhumatoïde | la rhumatologie pour tous

. Disponible,

A. Cotten, P. Philippe, and R. Flipo, Chapitre 3-Polyarthrite rhumatoïde, Imagerie Musculosquelettique : Pathologies Générales, pp.97-136, 2013.

B. L. Jonas and R. Roubey, 153-Polyarthrite rhumatoïde, Médecine interne de Netter, pp.1171-1177, 2011.

C. Cayzac, I. Diaz, P. Lapalud, J. Vendrell, B. Andreani et al., Mécanismes cellulaires de la réponse immune anti-FVIII chez les patients hémophiles A. Hématologie, vol.16, pp.372-81, 2010.

F. Pillon and Y. Michiels, Épidémiologie et physiopathologie de la polyarthrite rhumatoïde, Actual Pharm. déc, vol.52, issue.531, pp.1-2, 2013.

J. Morel, P. Miossec, and B. Combe, Immunopathologie de la polyarthrite rhumatoïde, EMCRhumatol-Orthopédie. mai, vol.1, issue.3, pp.218-248, 2004.

E. Esposito and S. Cuzzocrea, Anti-TNF therapy in the injured spinal cord, Trends Pharmacol Sci. 1 févr, vol.32, issue.2, pp.107-122, 2011.

C. Gaujoux-viala, L. Gossec, A. Cantagrel, M. Dougados, B. Fautrel et al., Recommandations de la Société française de rhumatologie pour la prise en charge de la polyarthrite rhumatoïde, Rev Rhum. juill, vol.81, issue.4, pp.303-315, 2014.

M. Merle, M. Isel, and S. Célérier, Chapitre 12-Polyarthrite rhumatoïde, Orthèses De la Main et du Poignet Protocoles De Rééducation, pp.171-94, 2012.

M. Brazier, P. Fardellone, and J. Moretto, 18-Traitement de la polyarthrite rhumatoïde, Pharmacie clinique et thérapeutique (3e édition entièrement revue, pp.367-85, 2008.

, VIDAL-NOVATREX 2,5 mg cp

. Vidal-salazopyrine, 500 mg cp enr gastrorésis

. Disponible,

. Vidal-arava, 10 mg cp pellic

. Disponible,

. Vidal-plaquenil, 200 mg cp pellic

. Disponible,

M. L. Stoll and A. C. Gotte, Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences, Biol Targets Ther. juin, vol.2, issue.2, pp.229-52, 2008.

. Vidal-enbrel, 50 mg sol inj en seringue préremplie

. Disponible,

K. N. Murray, A. R. Parry-jones, and A. Sm, Interleukin-1 and acute brain injury. Front Cell Neurosci, vol.9, 2015.
DOI : 10.3389/fncel.2015.00018

URL : https://www.frontiersin.org/articles/10.3389/fncel.2015.00018/pdf

R. , , vol.67, 2017.

, /(type)/name/(value)/kineret/(cip)/3400927732034#nav-buttons

O. Goldzweig and P. J. Hashkes, Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy, Drug Des Devel Ther. 26 janv, vol.5, pp.61-70, 2011.

. Vidal-orencia, 125 mg sol inj en stylo prérempli

. Disponible,

C. A. Janeway, K. Murphy, P. Travers, M. Walport, P. L. Masson et al., , 2009.

J. Pedersen, Inflammatory pathways of importance for management of inflammatory bowel disease, World J Gastroenterol, vol.20, issue.1, p.64, 2014.

, Remicade 100mg, poudre pour solution à diluer pour perfusion

, Humira 40mg, solution injectable en seringue préremplie

. Disponible,

, Cimzia 200mg, solution injectable

, Simponi 100mg, solution injectable en seringue préremplie

. Disponible,

J. Sany, Anticorps monoclonaux dans le traitement de la polyarthrite rhumatoïde : vers une révolution thérapeutique, C R Biol. avr, vol.329, issue.4, pp.228-268, 2006.
DOI : 10.1016/j.crvi.2005.12.008

M. Noack and P. Miossec, Selected cytokine pathways in rheumatoid arthritis, Semin Immunopathol. 17 févr, pp.1-19, 2017.

. Vidal-remicade, 100 mg pdre p sol diluer p perf

. Disponible,

, /(type)/name/(value)/simponi/(cip)/3400927568480#nav-buttons

, /(type)/name/(value)/humira/(cip)/3400936223059#nav-buttons

, /(type)/name/(value)/cimzia/(cip)/3400939732008#nav-buttons

V. Goëb, M. Ardizzone, L. Arnaud, J. Avouac, A. Baillet et al., Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française, Rev Rhum, vol.80, issue.5, pp.459-66, 2013.

H. Marotte and P. Miossec, Biomarqueurs prédictifs de la réponse aux anti-TNF alpha dans la polyarthrite rhumatoïde. Rev Rhum, vol.77, pp.448-57, 2010.

M. Belhassen, C. Hudry, M. Woronoff, L. Lamezec, N. Gouyette et al., 32Maintien thérapeutique des anti TNF-alpha sous-cutanés dans la Polyarthrite Rhumatoïde, la Spondylarthrite Ankylosante et le Rhumatisme Psoriasique des patients naïfs de biothérapies en France, Rev Rhum, vol.83, 2016.

A. Frazier-mironer, M. Dougados, X. Mariette, A. Cantagrel, V. Deschamps et al., Taux de rétention de l'adalimumab, de l'étanercept et de l'infliximab en 1re ou 2e ligne de biothérapie chez les patients atteints de polyarthrite rhumatoïde en pratique courante, Rev Rhum. déc, vol.81, issue.6, pp.483-90, 2014.

S. Boussaid, S. Kochbati, L. Baili, D. B. Ben, F. Boussema et al., Lu-011-Maintenance thérapeutique des anti TNF au cours des Rhumatismes Inflammatoires Chronique, Rev Rhum, vol.83, pp.206-213, 2016.

L. Goff, B. Blanchard, F. Berthelot, J. Heymann, D. Maugars et al., Rôle de l'interleukine6 dans les destructions ostéoarticulaires et la perte osseuse systémique au cours de la polyarthrite rhumatoïde, Rev Rhum. mai, vol.77, issue.3, pp.233-241, 2010.

L. Kaly and I. Rosner, Tocilizumab-A novel therapy for non-organ-specific autoimmune diseases, Best Pract Res Clin Rheumatol. févr, vol.26, issue.1, pp.157-65, 2012.

, Roactemra 162 mg, solution injectable en seringue préremplie

G. W. Kim, N. R. Lee, R. H. Pi, Y. S. Lim, Y. M. Lee et al., IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future, Arch Pharm Res, vol.38, issue.5, pp.575-84, 2015.

, Roactemra 20mg/mL, solution à diluer pour perfusion

. Disponible,

, /(type)/name/(value)/roactemra/(cip)/3400927824845#nav-buttons

J. M. Kremer, R. Blanco, A. Halland, M. Brzosko, R. Burgos-vargas et al., Clinical efficacy and safety maintained up to 5 years in patients with rheumatoid arthritis treated with tocilizumab in a randomised trial, Clin Exp Rheumatol. août, vol.34, issue.4, pp.625-658, 2016.

M. Kihara, R. Davies, L. Kearsley-fleet, K. D. Watson, M. Lunt et al., Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis, Clin Rheumatol. 1 févr, vol.36, issue.2, pp.241-50, 2017.

L. Joffres, R. Emilie, C. Pereira-gillion, M. Herbette, C. Lucas et al., Lu-073Polyarthrite rhumatoïde et tocilizumab : Efficacité et tolérance lors du passage à la sous cutanée, Rev Rhum, vol.83, pp.237-245, 2016.

A. Kivitz, T. Wallace, E. Olech, M. Borofsky, J. Devenport et al., Long-Term Safety and Efficacy of Subcutaneously Administered Tocilizumab for Adult Rheumatoid Arthritis: A Multicenter Phase 3b Long-term Extension Study, Rheumatol Ther. déc, vol.3, issue.2, p.291, 2016.

R. Sakai, M. Tanaka, T. Nanki, K. Watanabe, H. Yamazaki et al., Drug retention rates and relevant risk factors for drug discontinuation due to adverse events in rheumatoid arthritis patients receiving anticytokine therapy with different target molecules, Ann Rheum Dis, vol.71, issue.11, pp.1820-1826, 2012.

N. Ferreira, I. , F. González, M. A. , M. Garrido et al., Two-year efficacy of tocilizumab in patients with active rheumatoid arthritis in clinical practice, Reumatol Clin. 10 mai, 2016.

J. Sibilia, J. Gottenberg, and M. X. , Le rituximab : une nouvelle possibilité thérapeutique dans la polyarthrite rhumatoïde. Rev Rhum, vol.75, pp.782-791, 2008.

P. Youinou, S. Hillion, C. Jamin, J. Pers, A. Saraux et al., B lymphocytes on the front line of autoimmunity, Autoimmun Rev, vol.5, pp.215-236, 2006.

, Mabthera 100mg, solution à diluer pour perfusion

. Disponible,

Z. Stamataki, S. Tilakaratne, D. H. Adams, and J. A. Mckeating, Rituximab Treatment in Hepatitis C Infection: An In Vitro Model to Study the Impact of B Cell Depletion on Virus Infectivity, PLoS ONE, vol.6, issue.9, 2011.

J. Sibilia, Surveillance et précautions à prendre lors d'un traitement par un immunomodulateur biologique, Rev Médecine Interne. déc, vol.31, pp.315-323, 2010.

C. Moyano, N. Simons, M. Beldjerd, T. Billey, L. Fouille-ribeyre et al., Lu-067-Analyse rétrospective de l'efficacité du rituximab dans le traitement de la polyarthrite rhumatoïde (PR) dans la vrai vie, Rev Rhum, vol.83, 2016.

L. Gossec, A. Danré, B. Combe, L. Loët, X. Tebib et al., Amélioration des résultats rapportés par les patients atteints de polyarthrite rhumatoïde traités par rituximab : évaluation ouverte de 175 patients, Rev Rhum. déc, vol.83, issue.6, pp.457-60, 2016.

F. Hanni, F. Mechid, R. Benaziez, N. Zehraoui, S. Ahmed et al., Di035-Tolérance du rituximab au cours de la polyarthrite rhumatoïde dans la vraie vie, Rev Rhum, vol.83, pp.182-185, 2016.

M. Pinto and A. M. Carmo, CD6 as a Therapeutic Target in Autoimmune Diseases: Successes and Challenges, BioDrugs. 1 juin, vol.27, issue.3, pp.191-202, 2013.

L. E. Aira, P. Hernández, D. Prada, A. Chico, J. A. Gómez et al., Immunological evaluation of rheumatoid arthritis patients treated with itolizumab. mAbs, vol.8, pp.187-95, 2015.

R. Menon and B. G. David, Itolizumab – a humanized anti-CD6 monoclonal antibody with a better side effects profile for the treatment of psoriasis

C. Clinical and . Dermatology, , 2015.

P. Hernández, E. Moreno, L. E. Aira, and P. C. Rodríguez, Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab, Curr Drug Targets, vol.17, issue.6, pp.666-77, 2016.

A. Chopra, S. Chandrashekara, R. Iyer, L. Rajasekhar, N. Shetty et al., Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study, Clin Rheumatol. 1 avr, vol.35, issue.4, pp.1059-64, 2016.

J. R. Kalden, Emerging Therapies for Rheumatoid Arthritis, Rheumatol Ther. 3 juin, vol.3, issue.1, pp.31-42, 2016.

S. Kunwar, K. Dahal, and S. Sharma, Anti-IL-17 therapy in treatment of rheumatoid arthritis: a systematic literature review and meta-analysis of randomized controlled trials, Rheumatol Int. août, vol.36, issue.8, pp.1065-75, 2016.

W. B. Van-den-berg and P. Miossec, IL-17 as a future therapeutic target for rheumatoid arthritis, Nat Rev Rheumatol. oct, vol.5, issue.10, pp.549-53, 2009.

L. Liu, J. Lu, B. W. Allan, Y. Tang, J. Tetreault et al., Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A, J Inflamm Res. 19 avr, vol.9, pp.39-50, 2016.

M. C. Genovese, D. K. Braun, J. S. Erickson, P. Berclaz, S. Banerjee et al., Safety and Efficacy of Open-label Subcutaneous Ixekizumab Treatment for 48 Weeks in a Phase II Study in Biologic-naive and TNF-IR Patients with Rheumatoid Arthritis, J Rheumatol. 1 févr, vol.43, issue.2, pp.289-97, 2016.

M. Sanford, K. Mckeage, and . Secukinumab, First Global Approval. Drugs. 1 févr, vol.75, issue.3, pp.329-367, 2015.

M. I. Koenders and W. B. Van-den-berg, Secukinumab for rheumatology: development and its potential place in therapy, Drug Des Devel Ther. 24 juin, vol.10, pp.2069-80, 2016.

W. Tlustochowicz, P. Rahman, B. Seriolo, G. Krammer, B. Porter et al., Efficacy and Safety of Subcutaneous and Intravenous Loading Dose Regimens of Secukinumab in Patients with Active Rheumatoid Arthritis: Results from a Randomized Phase II Study, J Rheumatol. 1 mars, vol.43, issue.3, pp.495-503, 2016.

G. R. Burmester, P. Durez, G. Shestakova, M. C. Genovese, H. Schulze-koops et al., Association of HLA-DRB1 alleles with clinical responses to the anti-interleukin-17A monoclonal antibody secukinumab in active rheumatoid arthritis, Rheumatology. 1 janv, vol.55, issue.1, pp.49-55, 2016.

K. Pavelka, Y. Chon, R. Newmark, S. Lin, S. Baumgartner et al., A Study to Evaluate the Safety, Tolerability, and Efficacy of Brodalumab in Subjects with Rheumatoid Arthritis and an Inadequate Response to Methotrexate, J Rheumatol. 1 juin, vol.42, issue.6, pp.912-921, 2015.

S. L. Greig, Brodalumab: First Global Approval, Drugs. sept, vol.76, issue.14, pp.1403-1415, 2016.

M. D. Franco, M. C. Gerardi, B. Lucchino, and F. Conti, Mavrilimumab: an evidence based review of its potential in the treatment of rheumatoid arthritis

, Core Evidence, 2014.

C. Crotti, M. G. Raimondo, A. Becciolini, M. Biggioggero, and E. G. Favalli, Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date, Drug Des Devel Ther. 13 janv, vol.11, pp.211-234, 2017.

A. B. Avci, E. Feist, and G. Burmester, Targeting GM-CSF in rheumatoid arthritis, Clin Exp Rheumatol. août, vol.34, issue.4, pp.39-44, 2016.

G. R. Burmester, I. B. Mcinnes, J. Kremer, P. Miranda, M. Korkosz et al., A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis, Ann Rheum Dis. 16 févr, 2017.

F. Behrens, P. P. Tak, M. Østergaard, R. Stoilov, P. Wiland et al., MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial, Ann Rheum Dis. juin, vol.74, issue.6, pp.1058-64, 2015.

P. E. Lazzerini, P. L. Capecchi, G. M. Guidelli, E. Selvi, M. Acampa et al., Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date, Drug Des Devel Ther. 26 sept, vol.10, pp.3083-98, 2016.

S. Shaw, T. Bourne, C. Meier, B. Carrington, R. Gelinas et al., Discovery and characterization of olokizumab. mAbs. 1 mai, vol.6, issue.3, pp.773-81, 2014.

M. C. Genovese, R. Fleischmann, D. Furst, N. Janssen, J. Carter et al., Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1607-1622, 2014.

Y. Tanaka and E. M. Mola, IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1595-1602, 2014.

T. Takeuchi, Y. Tanaka, H. Yamanaka, K. Amano, R. Nagamine et al., Efficacy and safety of olokizumab in Asian patients with moderate-to-severe rheumatoid arthritis, previously exposed to anti-TNF therapy: Results from a randomized phase II trial, Mod Rheumatol. 2 janv, vol.26, issue.1, pp.15-23, 2016.

R. R. June and N. J. Olsen, Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis, Expert Opin Biol Ther, vol.16, issue.10, pp.1303-1312, 2016.

T. Huizinga, R. M. Fleischmann, M. Jasson, A. R. Radin, J. Adelsberg et al., Sarilumab, a fully human monoclonal antibody against IL-6R? in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1626-1660, 2014.

V. Strand, M. Kosinski, C. Chen, G. Joseph, R. Rendas-baum et al., Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial, Arthritis Res Ther, vol.18, issue.1, 2016.

M. C. Genovese, R. Fleischmann, A. J. Kivitz, M. Rell-bakalarska, R. Martincova et al., Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study, Arthritis Rheumatol. 1 juin, vol.67, issue.6, pp.1424-1461, 2015.

R. Fleischmann, J. Van-adelsberg, Y. Lin, R. Castelar-pinheiro-g-da, J. Brzezicki et al., Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors, Arthritis Rheumatol. 1 févr, vol.69, issue.2, pp.277-90, 2017.
DOI : 10.1002/art.39944

URL : https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.39944

G. R. Burmester, Y. Lin, R. Patel, J. Adelsberg, . Van et al., Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial, Ann Rheum Dis, vol.16, 2016.

J. M. Reichert, Antibodies to watch in 2017, mAbs. 17 févr, vol.9, issue.2, pp.167-81, 2017.
DOI : 10.1080/19420862.2016.1269580

URL : https://www.tandfonline.com/doi/pdf/10.1080/19420862.2016.1269580?needAccess=true

Y. Zhuang, D. E. De-vries, Z. Xu, S. J. Marciniak, D. Chen et al., Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach, J Clin Pharmacol. 1 déc, vol.55, issue.12, pp.1386-94, 2015.

J. S. Smolen, M. E. Weinblatt, S. Sheng, Y. Zhuang, and B. Hsu, Sirukumab, a human antiinterleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dosefinding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy, Ann Rheum Dis. 1 sept, vol.73, issue.9, pp.1616-1641, 2014.

D. Aletaha, I. Bingham, . Co, Y. Tanaka, P. Agarwal et al., Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. The Lancet

. Disponible,

M. E. Weinblatt, P. Mease, E. Mysler, T. Takeuchi, E. Drescher et al., The Efficacy and Safety of Subcutaneous Clazakizumab in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results From a Multinational, Phase IIb, Randomized, Double-Blind, Placebo/Active-Controlled, DoseRanging Study, Arthritis Rheumatol, vol.67, issue.10, pp.2591-600, 2015.

, UPDATE: FDA rejects Sanofi's promising Rheumatoid Arthritis Drug

. Labiotech and . Eu, , 2016.

A. Chakraborty, S. Tannenbaum, C. Rordorf, P. J. Lowe, D. Floch et al., Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human AntiInterleukin-1? Monoclonal Antibody, Clin Pharmacokinet. juin, vol.51, issue.6, p.1, 2012.

. Netgen and . Rhumatologie,

. Revue-médicale-suisse,

. Disponible,

I. Allam, R. Djidjik, N. Ouikhlef, S. Louahchi, N. Raaf et al., Étude des polymorphismes des gènes de l'interleukine-1 et de l'antagoniste du récepteur de l'interleukine-1 chez des patients atteints de polyarthrite rhumatoïde, Pathol Biol. déc, vol.61, issue.6, pp.264-272, 2013.

R. Alten, J. Gomez-reino, P. Durez, A. Beaulieu, A. Sebba et al., Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study, BMC Musculoskelet Disord, vol.12, p.153, 2011.

A. I. Abushouk, H. Ahmed, A. Ismail, A. Elmaraezy, A. S. Badr et al., Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis, Rheumatol Int. 24 févr, 2017.

P. P. Tak, P. J. Mease, M. C. Genovese, J. Kremer, B. Haraoui et al., Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial, Arthritis Rheum. 1 févr, vol.64, issue.2, pp.360-70, 2012.

W. Rigby, H. Tony, K. Oelke, B. Combe, A. Laster et al., Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebocontrolled, parallel-group phase III trial, Arthritis Rheum. 1 févr, vol.64, issue.2, pp.350-359, 2012.

W. Stohl, J. Gomez-reino, E. Olech, J. Dudler, R. M. Fleischmann et al., Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial, Ann Rheum Dis. 1 août, vol.71, issue.8, pp.1289-96, 2012.

P. Emery, W. Rigby, P. P. Tak, T. Dörner, E. Olech et al., Safety with Ocrelizumab in Rheumatoid Arthritis: Results from the Ocrelizumab Phase III Program, PLOS ONE. févr, vol.9, issue.2, p.87379, 2014.

P. C. Taylor, E. Quattrocchi, S. Mallett, R. Kurrasch, J. Petersen et al., Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial, Ann Rheum Dis. 1 déc, vol.70, issue.12, pp.2119-2144, 2011.

Y. M. Pers and C. Jorgensen, Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases, Immunotherapy. sept, vol.8, issue.9, pp.1091-1097, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01834266

E. Quattrocchi, M. Østergaard, P. C. Taylor, R. F. Vollenhoven, . Van et al., Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, Rheumatoid Arthritis: Results from Three Clinical Trials, vol.11, p.157961, 2016.

R. Kurrasch, J. C. Brown, M. Chu, J. Craigen, P. Overend et al., Subcutaneously Administered Ofatumumab in Rheumatoid Arthritis: A Phase I/II Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics, J Rheumatol. 1 juill, vol.40, issue.7, pp.1089-96, 2013.

M. Greenwald, L. Szczepanski, A. Kennedy, M. Veenhuizen, W. J. Komocsar et al., A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis, Arthritis Res Ther, vol.16, p.415, 2014.

M. Schiff, B. Combe, T. Dörner, J. M. Kremer, T. W. Huizinga et al., Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study, RMD Open. 1 août, vol.1, issue.1, p.37, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01901102

J. S. Smolen, M. E. Weinblatt, . Heijde-d-van-der, W. Rigby, . Vollenhoven-r-van et al., Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind study, Ann Rheum Dis. 1 août, vol.74, issue.8, pp.1567-70, 2015.

J. Witcher, R. Fleischmann, V. L. Chindalore, R. J. Hansen, L. Hu et al., Pharmacokinetics and safety of single doses of tabalumab in subjects with rheumatoid arthritis or systemic lupus erythematosus, Br J Clin Pharmacol. 1 mai, vol.81, issue.5, pp.908-925, 2016.

F. Mackay and C. R. Mackay, The role of BAFF in B-cell maturation, T-cell activation and autoimmunity, Trends Immunol. 1 mars, vol.23, issue.3, pp.113-118, 2002.

R. Byng-maddick and M. R. Ehrenstein, The impact of biological therapy on regulatory T cells in rheumatoid arthritis, Rheumatology. 1 mai, vol.54, issue.5, pp.768-75, 2015.

S. Humblet-baron and F. Baron, Boosting regulatory T-cell function with the humanized CD4-specific humanized monoclonal antibody Tregalizumab (BT-061), Immunol Cell Biol. avr, vol.93, issue.4, pp.321-323, 2015.

M. König, F. Rharbaoui, S. Aigner, B. Dälken, and J. Schüttrumpf, Tregalizumab-A Monoclonal Antibody to Target Regulatory T Cells. Front Immunol, vol.25

B. Helling, M. König, B. Dälken, A. Engling, W. Krömer et al., A specific CD4 epitope bound by tregalizumab mediates activation of regulatory T cells by a unique signaling pathway, Immunol Cell Biol. avr, vol.93, issue.4, pp.396-405, 2015.

C. Uherek, A. Engling, and B. Daelken, The novel regulatory T cell (Treg) agonistic monoclonal antibody (mAb) tregalizumab (BT-061): further characterization of mechanism of action, epitope binding, and clinical effects in patients with rheumatoid arthritis, Biotest-Nat Life, 2011.

J. S. Smolen, S. K. Agarwal, E. Ilivanova, X. L. Xu, Y. Miao et al., A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate, Ann Rheum Dis. 13 janv, 2017.

S. L. Gaffen, R. Jain, A. V. Garg, and D. J. Cua, IL-23-IL-17 immune axis: Discovery, Mechanistic Understanding, and Clinical Testing, Nat Rev Immunol. sept, vol.14, issue.9, pp.585-600, 2014.

M. Teng, E. P. Bowman, J. J. Mcelwee, M. J. Smyth, J. Casanova et al., IL-12 and IL-23 cytokines: from discovery to targeted therapies for immune-mediated inflammatory diseases, Nat Med. juill, vol.21, issue.7, pp.719-748, 2015.

Y. Michiels and F. Pillon, L'accompagnement du patient atteint de polyarthrite rhumatoïde à l'officine, Actual Pharm. déc, vol.52, issue.531, pp.14-21, 2013.

C. Bardet, J. Buxeraud, and J. Cook-moreau, Délivrance d'un anticorps monoclonal à l'officine. Actual Pharm, vol.52, pp.33-37, 2013.

, Cespharm-Comprendre la polyarthrite rhumatoïde-brochure

G. , LD-La prise en charge de votre polyarthrite rhumatoïde

, Fiches traitements-Association Nationale de Défense contre l'Arthrite Rhumatoïde

, AFP-Site d'information sur la Polyarthrite Rhumatoïde et les Rhumatismes Inflammatoires Chroniques

, Parcours bon usage anti-TNF alpha-Maladies inflammatoires chroniques

V. Goëb, M. Ardizzone, L. Arnaud, J. Avouac, A. Baillet et al., Conseils d'utilisation des traitements anti-TNF et recommandations nationales de bonne pratique labellisées par la Haute Autorité de santé française, Rev Rhum, vol.80, issue.5, pp.459-66, 2013.

, Club Rhumatismes et Inflammations-Fiches pratiques & RecommandationsTraitements anti-TNFa et suivi de tolérance

P. Aleth, Idées reçues ou autres questions ? | la rhumatologie pour tous, 2016.

F. Verhoeven, N. Tordi, C. Prati, C. Demougeot, F. Mougin et al., Activité physique et polyarthrite rhumatoïde, Rev Rhum. mars, vol.83, issue.2, pp.99-104, 2016.

K. Nguyen-huu, M. Pugibet, P. Vergne-salle, P. Bertin, and . Pc, 56A-Régimes diététiques et polyarthrite rhumatoïde : Revue systématique de la littérature, Rev Rhum. nov, vol.83, pp.73-77, 2016.

C. Varoquier, J. Salmon, F. Danion, E. Chatelus, C. Sordet et al., Les effets des régimes et des stratégies diététiques dans la polyarthrite rhumatoïde. Rev Rhum, vol.82, pp.283-90, 2015.